Europe is producing world-class medical technology — but are regulation, limited access to capital and fragmented markets making it harder for European MedTech startups to actually succeed?
Live from TechBBQ 2026, Christian Arnø sits down with Jack Eamon-Basken, Managing Partner at MedTech Bridge, to explore the difference between building and commercializing medical technology in Europe and the United States.
With a background spanning biotechnology, pharma, MedTech and company leadership, Jack now helps European MedTech companies navigate the US market — from go-to-market strategy and reimbursement to regulatory pathways,
investors and commercial networks. In this episode, we discuss:
• Why European MedTech companies increasingly look toward the US
• The difference between European and American go-to-market strategies
• Why FDA clearance is only one part of successfully entering the US
• Reimbursement, hospitals, insurers and understanding who actually pays
• Whether European regulation is slowing down innovation
• Why access to capital looks so different in the US
• AI and the future of medical technology
• Why European founders may need to think — and raise — much bigger
One story captures the difference particularly well: Jack describes a European company looking to raise around $4.5 million in the US, only to essentially be told to come back when they could explain how they would use $50 million.
Europe has the science.
Europe has the talent.
The question is whether we are creating the conditions for the companies built here to scale here as well — or whether the next generation of European MedTech success stories will ultimately be commercialized somewhere else.
🎙️ The BuildingBusiness Podcast — live from TechBBQ 2026
Subscribe for more conversations with founders, operators and people building the technologies shaping what comes next.
#TechBBQ #MedTech #Startups #HealthcareInnovation #Entrepreneurship #Biotech #MedicalTechnology #StartupFunding #FDA #HealthTech #BuildingBusinessPodcast